US Stock Movement | Intellia Therapeutics plummets over 45% as patient dosing and screening for the paused Phase 3 clinical trial of nex-z are halted

On Monday, Intellia Therapeutics plummeted over 45%, closing at $13.90. In terms of news, Intellia Therapeutics announced that it has suspended patient dosing and screening for its two Phase III clinical trials regarding nex-z. These trials are aimed at patients with transthyretin amyloidosis with cardiomyopathy and polyneuropathy, due to a report from a patient experiencing Grade 4 elevation of liver transaminases and increased total bilirubin after medication. The patient has been hospitalized and is receiving medical intervention. Intellia stated that it is consulting with experts and considering potential risk mitigation strategies, while also communicating with regulatory agencies, aiming to resume trial recruitment as soon as appropriate